Replimune: Multiple Shots On Goal But A High Risk Binary Approaches

Replimune’s RP1+nivolumab melanoma BLA faces an FDA decision by Apr 10, 2026. The current cash runway extends to Q1'27. See ...
Nasdaq

Wall Street Analysts Predict a 65.72% Upside in Replimune Group (REPL): Here's What You Should Know

Shares of Replimune Group, Inc. (REPL) have gained 0.7% over the past four weeks to close the last trading session at $7.76, but there could still be a solid upside left in the stock if short-term ...
GitHub

A Node.js/TypeScript implementation of Recursive Language Models based on the research paper arXiv:2512.24601 by Zhang, Kraska, and Khattab.

RLM enables LLMs to process arbitrarily long contexts by treating them as an external environment that can be programmatically explored via a JavaScript REPL. Instead of feeding entire long documents ...